Avatar

The Future of CAR T Therapies in Myeloma in 2018

By Nina Shah 3 Videos
June 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas

Featured Video

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas

Related Content

AUTOPLAY
International Society of Geriatric Oncology

19th Conference of the International Society of Geriatric Oncology

Thu, Nov 14, 2019
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
17:44
UChicago CAR T-Cell Symposium 2019

Current Grading and Management Strategies of CAR-T Toxicities: Cytokine ...

Feat. S. Kosuri
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
13:23
Parameswaran Hari

CAR T and NK Cell Therapy in Myeloma

22:47
UChicago CAR T-Cell Symposium 2019

Patient Selection for CAR T-Cell Therapy: Therapeutic Benefits, Discussi...

Feat. M. Leukam
06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
09:49
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

15:02
Krina Patel

Clinical Trials in Myeloma in 2018

10:17
Amgen Oncology

Multiple Myeloma: Use of Proteasome Inhibitor at First Relapse-A Case Study

Feat. H. Kaya
07:23
Indy Hematology Review

Novel Immune Therapies in Myeloma: BCMA Immunotoxin, Bites, and CAR T cells

Feat. K. Anderson
15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas
16:22
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

FDA Approves Selinexor for Refractory Multiple Myeloma, STORM Study

Feat. S. Jagannath
22:21
UChicago CAR T-Cell Symposium 2019

Immune Regulation and Chimeric Antigen Receptor (CAR) T-Cell Therapy: Me...

Feat. J. Labelle
12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:10
Krina Patel

Developing CAR T-cells in Multiple Myeloma

15:47
Society of Hematologic Oncology Sixth Annual Meeting

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial